Ongoing Ebola transmission in the Democratic Republic of the Congo since mid-May 2026 has driven trader focus, with over 7,600 confirmed cases and nearly 3,700 deaths reported across seven provinces by mid-September, fueled by the Bundibugyo strain, conflict-related displacement, and tracing challenges. Limited imported cases reached Uganda (around 20, with the cluster contained and no new infections since June) and one in France, but no sustained community spread has occurred outside DRC. Neighboring countries face elevated risk from cross-border movement, though response efforts and the absence of vaccines specific to this strain shape uncertainty around further international detections before year-end.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedWhich countries will have an Ebola case in 2026?
Which countries will have an Ebola case in 2026?
$39,193 Vol.
Dec 31, 2026
South Sudan
47%
Rwanda
21%
Burundi
38%
United States
20%
Canada
33%
Kenya
23%
India
44%
Republic of the Congo
24%
Nigeria
49%
Ethiopia
52%
Somalia
35%
China
12%
$39,193 Vol.
South Sudan
$4,406 Vol.
47%
Rwanda
$2,216 Vol.
21%
Burundi
$229 Vol.
38%
United States
$10,886 Vol.
20%
Canada
$2,307 Vol.
33%
Kenya
$237 Vol.
23%
India
$737 Vol.
44%
Republic of the Congo
$12,408 Vol.
24%
Nigeria
$25 Vol.
49%
Ethiopia
$107 Vol.
52%
Somalia
$129 Vol.
35%
China
$3,551 Vol.
12%
This market will resolve to "Yes" if there is a confirmed case of Ebola in the territory of the specified country reported between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.Ongoing Ebola transmission in the Democratic Republic of the Congo since mid-May 2026 has driven trader focus, with over 7,600 confirmed cases and nearly 3,700 deaths reported across seven provinces by mid-September, fueled by the Bundibugyo strain, conflict-related displacement, and tracing challenges. Limited imported cases reached Uganda (around 20, with the cluster contained and no new infections since June) and one in France, but no sustained community spread has occurred outside DRC. Neighboring countries face elevated risk from cross-border movement, though response efforts and the absence of vaccines specific to this strain shape uncertainty around further international detections before year-end.
This market will resolve to "Yes" if there is a confirmed case of Ebola in the territory of the specified country reported between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.
Market Opened: May 22, 2026, 12:35 PM ET
Volume
$39,193End Date
Jan 1, 2027Market Opened
May 22, 2026, 12:35 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if there is a confirmed case of Ebola in the territory of the specified country reported between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.Ongoing Ebola transmission in the Democratic Republic of the Congo since mid-May 2026 has driven trader focus, with over 7,600 confirmed cases and nearly 3,700 deaths reported across seven provinces by mid-September, fueled by the Bundibugyo strain, conflict-related displacement, and tracing challenges. Limited imported cases reached Uganda (around 20, with the cluster contained and no new infections since June) and one in France, but no sustained community spread has occurred outside DRC. Neighboring countries face elevated risk from cross-border movement, though response efforts and the absence of vaccines specific to this strain shape uncertainty around further international detections before year-end.
This market will resolve to "Yes" if there is a confirmed case of Ebola in the territory of the specified country reported between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.
Volume
$39,193End Date
Jan 1, 2027Market Opened
May 22, 2026, 12:35 PM ETResolver
0x65070BE91...Ongoing Ebola transmission in the Democratic Republic of the Congo since mid-May 2026 has driven trader focus, with over 7,600 confirmed cases and nearly 3,700 deaths reported across seven provinces by mid-September, fueled by the Bundibugyo strain, conflict-related displacement, and tracing challenges. Limited imported cases reached Uganda (around 20, with the cluster contained and no new infections since June) and one in France, but no sustained community spread has occurred outside DRC. Neighboring countries face elevated risk from cross-border movement, though response efforts and the absence of vaccines specific to this strain shape uncertainty around further international detections before year-end.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions